Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.

Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N.

JAMA. 2000 Apr 5;283(13):1723-30.

PMID:
10755499
2.

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.

Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RM.

Crit Care Med. 1995 Jun;23(6):994-1006. Erratum in: Crit Care Med 1995 Sep;23(9):1616.

PMID:
7774238
3.

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al.

JAMA. 1991 Aug 28;266(8):1097-102.

PMID:
1865542
4.

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller MD, Sollet JP, Wolff M, Holzapfel L, Zeni F, Vedrinne JM, de Vathaire F, Gourlay ML, Guinot P, Mira JP.

Crit Care Med. 1998 Dec;26(12):1963-71.

PMID:
9875905
5.

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.

Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J; Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators.

Crit Care Med. 2009 Nov;37(11):2929-38. doi: 10.1097/CCM.0b013e3181b0266c.

PMID:
19770753
6.

Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis.

Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ.

Crit Care Med. 1992 Jun;20(6):730-5.

PMID:
1597023
7.
8.

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.

Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, Zaloga G, Maki D, Silverstein J, Tobias JK, Haenftling K, Black G, Cowens JW; MAB-T88 Sepsis Study Group.

Crit Care Med. 2003 Feb;31(2):419-27.

PMID:
12576946
9.

Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.

Barriere SL, Guglielmo BJ.

Clin Pharm. 1992 Mar;11(3):223-35. Review.

PMID:
1611812
10.

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR.

Ann Intern Med. 1994 Jul 1;121(1):1-5.

PMID:
8198341
11.

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al.

JAMA. 1995 Mar 22-29;273(12):934-41.

PMID:
7884952
12.

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A.

JAMA. 1997 May 21;277(19):1531-8.

PMID:
9153367
13.

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.

Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP, et al.

Crit Care Med. 1994 Nov;22(11):1720-8.

PMID:
7956274
15.

Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections.

Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ.

Prog Clin Biol Res. 1991;367:179-86.

PMID:
1924426
16.

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M.

Crit Care Med. 1997 Jul;25(7):1115-24.

PMID:
9233735
17.

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.

Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators.

Crit Care Med. 2004 Nov;32(11):2173-82.

PMID:
15640628
18.

Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis.

Reinhart K, Meier-Hellmann A, Beale R, Forst H, Boehm D, Willatts S, Rothe KF, Adolph M, Hoffmann JE, Boehme M, Bredle DL; EASy-Study Group.

Crit Care Med. 2004 Aug;32(8):1662-8.

PMID:
15286541
19.

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al.

N Engl J Med. 1991 Feb 14;324(7):429-36.

20.

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.

Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M.

Crit Care Med. 2001 Apr;29(4):765-9.

PMID:
11373466

Supplemental Content

Support Center